General Description
Tiludronate Disodium is a bisphosphonate inhibitor of bone resorption used for the treatment of Paget's disease of bone (osteitis deformans) and hypercalcemia of malignancy. Its molecular structure features a chloro-thienyl side chain attached to the bisphosphonate backbone, which confers moderate potency and a distinct binding profile to bone mineral compared to other bisphosphonates.
Mechanism of Action
Tiludronate Disodium localizes to bone hydroxyapatite mineral surfaces where it is internalized by osteoclasts during bone resorption. Once inside the osteoclast, it inhibits the enzyme farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway, preventing the synthesis of isoprenoid lipids required for post-translational modification (prenylation) of small GTPase signaling proteins essential for osteoclast ruffled border formation, cytoskeletal organization, and survival. This causes osteoclast apoptosis and reduces bone resorption.
Application
Tiludronate Disodium is indicated for the treatment of Paget's disease of bone, where it normalizes elevated bone turnover markers and reduces bone pain, deformity, and fracture risk.